These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 12091877)

  • 1. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
    Luttun A; Tjwa M; Moons L; Wu Y; Angelillo-Scherrer A; Liao F; Nagy JA; Hooper A; Priller J; De Klerck B; Compernolle V; Daci E; Bohlen P; Dewerchin M; Herbert JM; Fava R; Matthys P; Carmeliet G; Collen D; Dvorak HF; Hicklin DJ; Carmeliet P
    Nat Med; 2002 Aug; 8(8):831-40. PubMed ID: 12091877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
    Autiero M; Waltenberger J; Communi D; Kranz A; Moons L; Lambrechts D; Kroll J; Plaisance S; De Mol M; Bono F; Kliche S; Fellbrich G; Ballmer-Hofer K; Maglione D; Mayr-Beyrle U; Dewerchin M; Dombrowski S; Stanimirovic D; Van Hummelen P; Dehio C; Hicklin DJ; Persico G; Herbert JM; Communi D; Shibuya M; Collen D; Conway EM; Carmeliet P
    Nat Med; 2003 Jul; 9(7):936-43. PubMed ID: 12796773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders.
    Luttun A; Tjwa M; Carmeliet P
    Ann N Y Acad Sci; 2002 Dec; 979():80-93. PubMed ID: 12543719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.
    Viglietto G; Romano A; Manzo G; Chiappetta G; Paoletti I; Califano D; Galati MG; Mauriello V; Bruni P; Lago CT; Fusco A; Persico MG
    Oncogene; 1997 Nov; 15(22):2687-98. PubMed ID: 9400995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1.
    Landgren E; Schiller P; Cao Y; Claesson-Welsh L
    Oncogene; 1998 Jan; 16(3):359-67. PubMed ID: 9467961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.
    Cao Y; Chen H; Zhou L; Chiang MK; Anand-Apte B; Weatherbee JA; Wang Y; Fang F; Flanagan JG; Tsang ML
    J Biol Chem; 1996 Feb; 271(6):3154-62. PubMed ID: 8621715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
    Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
    Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
    Carmeliet P; Moons L; Luttun A; Vincenti V; Compernolle V; De Mol M; Wu Y; Bono F; Devy L; Beck H; Scholz D; Acker T; DiPalma T; Dewerchin M; Noel A; Stalmans I; Barra A; Blacher S; VandenDriessche T; Ponten A; Eriksson U; Plate KH; Foidart JM; Schaper W; Charnock-Jones DS; Hicklin DJ; Herbert JM; Collen D; Persico MG
    Nat Med; 2001 May; 7(5):575-83. PubMed ID: 11329059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines.
    Viglietto G; Maglione D; Rambaldi M; Cerutti J; Romano A; Trapasso F; Fedele M; Ippolito P; Chiappetta G; Botti G
    Oncogene; 1995 Oct; 11(8):1569-79. PubMed ID: 7478581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies.
    Eriksson U; Alitalo K
    Nat Med; 2002 Aug; 8(8):775-7. PubMed ID: 12152025
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
    Warren RS; Yuan H; Matli MR; Gillett NA; Ferrara N
    J Clin Invest; 1995 Apr; 95(4):1789-97. PubMed ID: 7535799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review.
    Ahmed A; Dunk C; Ahmad S; Khaliq A
    Placenta; 2000; 21 Suppl A():S16-24. PubMed ID: 10831117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling.
    Beck H; Acker T; Püschel AW; Fujisawa H; Carmeliet P; Plate KH
    J Neuropathol Exp Neurol; 2002 Apr; 61(4):339-50. PubMed ID: 11939589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
    Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
    Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers.
    Eriksson A; Cao R; Pawliuk R; Berg SM; Tsang M; Zhou D; Fleet C; Tritsaris K; Dissing S; Leboulch P; Cao Y
    Cancer Cell; 2002 Feb; 1(1):99-108. PubMed ID: 12086892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects.
    Epstein SE; Kornowski R; Fuchs S; Dvorak HF
    Circulation; 2001 Jul; 104(1):115-9. PubMed ID: 11435348
    [No Abstract]   [Full Text] [Related]  

  • 20. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1.
    Soini Y; Puhakka A; Kahlos K; Säily M; Pääkkö P; Koistinen P; Kinnula V
    Histopathology; 2001 Aug; 39(2):179-86. PubMed ID: 11493335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.